T細胞療法の市場規模・予測（2020年～2030年）、世界・地域シェア、動向、成長機会分析レポートの対象範囲モダリティ別（研究、商業化）、治療タイプ別（CAR T細胞療法、T細胞受容体（TCR）ベース）、適応症別（血液悪性腫瘍、固形腫瘍）、地域別（北米、欧州、アジア太平洋、中南米）

T Cell Therapy Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], Indication (Hematologic Malignancies and Solid Tumors), and Geography (North America, Europe, Asia Pacific, and South and Central America)

弊社の最新調査レポート「T細胞療法の市場予測（2020-2030年）、世界・地域シェア、動向、成長機会分析-モダリティ別、治療タイプ別、適応症別」によると、T細胞療法の市場規模は2022年に27億5,400万米ドルと評価... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
The Insight Partners ザ・インサイトパートナーズ	2023年9月14日	US$4,550 シングルユーザライセンスライセンス・価格情報注文方法はこちら	138	英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

サマリー

弊社の最新調査レポート「T細胞療法の市場予測（2020-2030年）、世界・地域シェア、動向、成長機会分析-モダリティ別、治療タイプ別、適応症別」によると、T細胞療法の市場規模は2022年に27億5,400万米ドルと評価され、2030年には90億3,501万米ドルに達すると予測されています。2020～2030年の年平均成長率は16.0%と推定される。

がん治療で最も有望な手技のひとつがT細胞療法であり、その応用を拡大するための前臨床および臨床研究が年々増加している。CAR T細胞療法もまた、がん専門医や学者の間で関心を集めている。世界的ながん罹患率の増加とT細胞療法の承認件数の増加が、T細胞療法市場の成長を後押ししている。また、臨床試験中のCAR T細胞療法の数が増加していることも、今後数年間のT細胞療法市場の成長を後押しすると予想される。

CAR T細胞療法の現在の状況は、複数の医薬品承認、豊富なパイプライン、進行中の多くの臨床試験により有望である。CAR T細胞療法のパイプラインは様々な臨床開発段階にあり、大手製薬企業はCAR T細胞療法の競争領域におけるパイプラインスペースと将来の成長可能性を前進させるべく取り組んでいる。

- 2022年11月、Peter MacCallum Cancer CentreとCartherics Pty Ltdは、皮膚T細胞リンパ腫（CTCL）治療のためのCartherics独自の自己CAR T細胞療法（CTH-001）を開発するための共同開発プログラム契約（CDPA）を締結した。共同研究の主な内容は、CTH-001の臨床規模での製造と第I相臨床試験の実施である。まず、難治性CTCL患者6人を登録する予定である。

- JWセラピューティクスの薬剤JWCAR029は、CD19を標的とするCAR T細胞製剤で、進行したリンパ腫や白血病の治療を目的としている。この分子は現在、開発の第II相段階にある。JWCAR029は当初、再発難治性DLBCLを中心としたB細胞悪性腫瘍の治療薬として研究されている。

- ギリアド・サイエンシズ社の薬剤KTE-X19は、現在研究中の自己CD19 CAR T細胞療法である。この薬剤は、T細胞選択とリンパ球濃縮を含むXLPプロセスを用いて製造される。KTE-X19が研究されている特定のB細胞悪性腫瘍ではリンパ球濃縮が必要である。KTE-X19は現在、成人および小児の急性リンパ性白血病の治療薬として第II相臨床試験段階にある。FDAはBrexucabtagene autoleucel（旧KTE-X19；Tecartus社）を再発または難治性のマントル細胞リンパ腫（MCL）の成人患者の治療薬として承認した。

- ZUMA-3は、成人の再発/難治性（R/R）B細胞性急性リンパ芽球性白血病（B-ALL）を対象に、自己抗CD19 CAR T細胞療法であるKTE-X19を評価する第1/2相試験である。

- mRNA CAR T 細胞療法である Descartes-11 は、新たに診断された高リスクの多発性骨髄腫（MM）患者を対象とした第 II 相臨床試験に移行しました。Descartes-11 は CAR T 細胞分子を一過性に発現し、これらの治療薬に特徴的な毒性を回避します。すでに18人の患者を対象とした第I相試験（NCT03994705）が実施され、その結果、CAR T細胞治療によくみられるサイトカイン放出症候群や神経毒性などの有害事象は認められなかった。

このように、CAR T細胞治療に関する上記のパイプラインは、T細胞治療市場における新たなトレンドとして台頭しつつある。

モダリティ別T細胞療法市場インサイト

モダリティに基づき、T細胞療法市場は研究用と商業用に区分される。2022年には、商業化されたセグメントが市場で大きなシェアを占めている。さらに、同セグメントは予測期間中に最も急成長すると予想される。製品上市の増加と、がん治療におけるT細胞療法の利点に関する認知度の上昇が、商業化セグメントの成長を後押ししている。

治療タイプ別、T細胞療法市場 -Based Insights

治療タイプ別に見ると、T細胞療法市場はCAR T細胞療法とT細胞受容体（TCR）ベースに二分される。2022年には、CAR T細胞療法分野が市場で大きなシェアを占める。さらに、同セグメントは予測期間中、大きな成長率で成長する。キメラ抗原受容体（CAR）T細胞治療法では、患者から得たT細胞を人工的に生物工学的に改変し、腫瘍細胞を識別して付着できるCARを発現させる。CAR T細胞分野で事業を展開する企業は、提携、拡大、合意、パートナーシップ、新製品の発売などの戦略的展開に参入しており、T細胞療法市場の成長を促進している。例えば、2022年にFDAはJanssen Biotech, Inc.が製造するCARVYKTIを承認した。CARVYKTIは、キメラ抗原受容体T細胞を意味するCAR-Tと呼ばれる治療法の一種である。CARVYKTI（ciltacabtagene autoleucel）は、多発性骨髄腫と呼ばれる骨髄がんの成人患者に使用される治療薬です。CARVYKTIは、プロテアソーム阻害剤、免疫調節剤、および抗CD38モノクローナル抗体を含む、4種類以上の前治療歴のある再発または難治性の多発性骨髄腫の成人患者を治療します。

世界保健機関（WHO）、欧州がん患者連合（European Cancer Patient Coalition）、米国国立がん研究所（National Cancer Institute）は、T細胞療法市場に関する報告書作成時に参照した主要な一次情報源および二次情報源の一部である。

ページTOPに戻る

TABLE OF CONTENTS

1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 T Cell Therapy Market, by Geography (US$ Million)
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. T Cell Therapy Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. T Cell Therapy Market - Key Industry Dynamics
5.1 Market Drivers:
5.1.1 Growing Burden of Cancer Worldwide
5.1.2 Increasing Number of T-Cell Therapy Approvals
5.2 Market Restraints
5.2.1 Side-effects of CAR T-Cell Therapy
5.3 Market Opportunities
5.3.1 Growing Investment in T-Cell Therapy
5.4 Future Trends
5.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
5.5 Impact Analysis:
6. T Cell Therapy Market - Global Market Analysis
6.1 T Cell Therapy Market Revenue (US$ Mn), 2022 – 2030
7. Global T Cell Therapy Market – Revenue and Forecast to 2030 – by Modality
7.1 Overview
7.2 T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
7.3 Research
7.3.1 Overview
7.3.2 Research: T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Commercialized
7.4.1 Overview
7.4.2 Commercialized: T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8. Global T Cell Therapy Market – Revenue and Forecast to 2030 – by Therapy Type
8.1 Overview
8.2 T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
8.3 CAR T-cell Therapy
8.3.1 Overview
8.3.2 CAR T-cell Therapy: T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.4 T-cell Receptor (TCR)-based
8.4.1 Overview
8.4.2 T-cell Receptor (TCR)-based: T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9. Global T Cell Therapy Market – Revenue and Forecast to 2030 – by Indication
9.1 Overview
9.2 T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
9.3 Hematologic Malignancies
9.3.1 Overview
9.3.2 Hematologic Malignancies: T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9.3.3 Global T Cell Therapy Market, by Haematological Malignancies, 2020–2030 (US$ Million)
9.4 Solid Tumor
9.4.1 Overview
9.4.2 Solid Tumor: T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
10. T Cell Therapy Market - Geographical Analysis
10.1 North America T Cell Therapy Market, Revenue and Forecast To 2030
10.1.1 Overview
10.1.2 North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.3 North America: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.1.4 North America: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.5 North America: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.5.1 North America: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.1.5.2 North America T Cell Therapy Market, by Country
10.1.5.3 US
10.1.5.3.1 US T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.5.3.2 US: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.1.5.3.3 US: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.5.3.4 US: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.5.3.4.1 US: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.1.5.4 Canada
10.1.5.4.1 Canada T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.5.4.2 Canada: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.1.5.4.3 Canada: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.5.4.4 Canada: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.5.4.4.1 Canada: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.1.5.5 Mexico
10.1.5.5.1 Mexico T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.5.5.2 Mexico: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.1.5.5.3 Mexico: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.5.5.4 Mexico: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.5.5.4.1 Mexico: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.2 Europe T Cell Therapy Market, Revenue and Forecast to 2030
10.2.1 Overview
10.2.2 Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.3 Europe: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.2.4 Europe: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.5 Europe: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5.1 Europe: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.2.5.2 Europe T Cell Therapy Market, by Country
10.2.5.3 UK
10.2.5.3.1 UK T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.5.3.2 UK: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.2.5.3.3 UK: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.5.3.4 UK: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5.3.4.1 UK: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.2.5.4 Germany
10.2.5.4.1 Germany T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.5.4.2 Germany: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.2.5.4.3 Germany: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.5.4.4 Germany: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5.4.4.1 Germany: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.2.5.5 France
10.2.5.5.1 France T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.5.5.2 France: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.2.5.5.3 France: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.5.5.4 France: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5.5.4.1 France: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.2.5.6 Italy
10.2.5.6.1 Italy T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.5.6.2 Italy: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.2.5.6.3 Italy: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.5.6.4 Italy: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5.6.4.1 Italy: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.2.5.7 Spain
10.2.5.7.1 Spain T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.5.7.2 Spain: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.2.5.7.3 Spain: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.5.7.4 Spain: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5.7.4.1 Spain: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.2.5.8 Rest of Europe
10.2.5.8.1 Rest of Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.5.8.2 Rest of Europe: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.2.5.8.3 Rest of Europe: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.5.8.4 Rest of Europe: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5.8.4.1 Rest of Europe: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.3 Asia Pacific T Cell Therapy Market, Revenue and Forecast to 2030
10.3.1 Overview
10.3.2 Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.3 Asia Pacific: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.3.4 Asia Pacific: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.5 Asia Pacific: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.5.1 Asia Pacific: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.3.5.2 Asia Pacific T Cell Therapy Market, by Country
10.3.5.3 China
10.3.5.3.1 China T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.5.3.2 China: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.3.5.3.3 China: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.5.3.4 China: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.5.3.4.1 China: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.3.5.4 Japan
10.3.5.4.1 Japan T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.5.4.2 Japan: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.3.5.4.3 Japan: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.5.4.4 Japan: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.5.4.4.1 Japan: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.3.5.5 Australia
10.3.5.5.1 Australia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.5.5.2 Australia: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.3.5.5.3 Australia: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.5.5.4 Australia: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.5.5.4.1 Australia: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.3.5.6 South Korea
10.3.5.6.1 South Korea T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.5.6.2 South Korea: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.3.5.6.3 South Korea: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.5.6.4 South Korea: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.5.6.4.1 South Korea: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.3.5.7 Rest of Asia Pacific
10.3.5.7.1 Rest of Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.5.7.2 Rest of Asia Pacific: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.3.5.7.3 Rest of Asia Pacific: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.5.7.4 Rest of Asia Pacific: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.5.7.4.1 Rest of Asia Pacific: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.4 Middle East & Africa T Cell Therapy Market, Revenue and Forecast to 2030
10.4.1 Overview
10.4.2 Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.3 Middle East & Africa: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.4.4 Middle East & Africa: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5 Middle East & Africa: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.1 Middle East & Africa: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.4.5.2 Middle East & Africa T Cell Therapy Market, by Country
10.4.5.3 Saudi Arabia
10.4.5.3.1 Saudi Arabia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.3.2 Saudi Arabia: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.4.5.3.3 Saudi Arabia: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.3.4 Saudi Arabia: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.3.4.1 Saudi Arabia: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.4.5.4 Israel
10.4.5.4.1 Israel T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.4.2 Israel: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.4.5.4.3 Israel: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.4.4 Israel: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.4.4.1 Israel: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.4.5.5 Rest of Middle East & Africa
10.4.5.5.1 Rest of Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.5.2 Rest of Middle East & Africa: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.4.5.5.3 Rest of Middle East & Africa: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.5.4 Rest of Middle East & Africa: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.5.4.1 Rest of Middle East & Africa: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.5 South & Central America T Cell Therapy Market, Revenue and Forecast to 2030
10.5.1 Overview
10.5.2 South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.2.1 Brazil
10.5.2.1.1 Brazil T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.2.1.2 Brazil: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.5.2.1.3 Brazil: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.2.1.4 Brazil: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.2.1.4.1 Brazil: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
11. T Cell Therapy Market–Industry Landscape
11.1 Overview
11.2 Growth Strategies in T Cell Therapy Market
11.3 Organic Growth Strategies
11.3.1 Overview
11.4 Inorganic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Immunocore Holdings Plc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Legend Biotech Corp
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Janssen Global Services LLC
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Gilead Sciences Inc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Bristol-Myers Squibb Co
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Bluebird Bio Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Novartis AG
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 JW (Cayman) Therapeutics Co Ltd
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Cartesian Therapeutics Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Innovent Biologics Inc
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms

ページTOPに戻る

Table of Contents

Summary

According to our new research study on "T Cell Therapy Market Forecast (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis – by Modality, Therapy Type, and Indication," the T cell therapy market size was valued at US$ 2,754.00 million in 2022 and is expected to reach US$ 9,035.01 million by 2030. It is estimated to register a CAGR of 16.0% during 2020–2030.

One of the most promising procedures of cancer treatment is T cell therapy, and every year, an increasing number of pre-clinical and clinical research is being conducted to increase its application. CAR T cell therapy has also generated interest among oncologists and academics. The growing burden of cancer worldwide and an increasing number of T cell therapy approvals drive the growth of the T cell therapy market. Also, rising number of car t-cell therapies in clinical trials is expected to fuel T cell therapy market growth in the coming years.

The current landscape for CAR T-cell therapies is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Pipelines of CAR T-cell therapies are in various stages of clinical development; major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CAR T-cell therapy competitive domain.

• In November 2022, Peter MacCallum Cancer Centre and Cartherics Pty Ltd entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics' proprietary autologous CAR T cell therapy (CTH-001) for treating cutaneous T-cell lymphoma (CTCL). The key aspects of the collaborative research are setting up clinical-scale manufacturing of CTH-001 and conducting a Phase I clinical trial. It will initially enroll six patients with refractory CTCL.

• JW Therapeutics drug JWCAR029 is a CAR T cell product that targets CD19 and is intended to treat advanced lymphoma and leukemia. The molecule is currently in Phase II of development. JWCAR029 is initially being investigated for treating B-cell malignancies, focusing on relapsed and refractory DLBCL.

• Gilead Sciences drug KTE-X19 is an autologous CD19 CAR T-cell therapy under investigation. The drug is manufactured using the XLP process, including T-cell selection and lymphocyte enrichment. Lymphocyte enrichment is required in certain B-cell malignancies for which KTE-X19 is being studied. KTE-X19 is currently in Phase II clinical trials for the treatment of both adult and pediatric acute lymphocytic leukemia. The FDA has approved Brexucabtagene autoleucel (formerly KTE-X19; Tecartus) for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL).

• ZUMA-3 is a Phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).

• Descartes-11, a mRNA CAR T-cell therapy, has moved into a Phase II clinical trial for newly diagnosed, high-risk multiple myeloma (MM) patients. Descartes-11 expresses CAR T-cell molecules transiently and avoids some characteristic toxicities of these therapeutic agents. A Phase I study (NCT03994705) of 18 patients has already been undertaken, and results showed no evidence of cytokine release syndrome or neurotoxicity-adverse events commonly associated with CAR T-cell treatment.

Thus, the pipelines above for CAR T-cell therapies are emerging as a new trend in the T cell therapy market.

By Modality, T Cell Therapy Market-Based Insights

Based on modality, the T cell therapy market is segmented into research and commercialized. In 2022, the commercialized segment held the larger share of the market. Moreover, the same segment is expected to grow fastest during the forecast period. An increase in product launches and a rise in awareness about the benefits of T cell therapy for cancer treatment fueling the growth of the commercialized segment.

By Therapy Type, T Cell Therapy Market -Based Insights

Based on therapy type, the T cell therapy market is bifurcated into CAR T cell therapy and T cell receptor (TCR)-based. In 2022, the CAR T cell therapy segment held the larger share of the market. Moreover, the same segment will grow at a significant growth rate during the forecast period. In the chimeric antigen receptor (CAR) T cell therapy technique, T cells obtained from patients are artificially bioengineered to express CARs that can identify and attach to the tumor cells. The companies are entering into strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches by companies operating in the CAR T cell segment, fueling the T cell therapy market growth. For instance, in 2022, FDA approved CARVYKTI manufactured by Janssen Biotech, Inc. CARVYKTI is a kind of therapy called CAR-T—which stands for chimeric antigen receptor T cell. CARVYKTI (ciltacabtagene autoleucel) is a treatment used for adult patients with bone marrow cancer called multiple myeloma. CARVYKTI treats adult patients with relapsed or refractory multiple myeloma after four or more former lines of therapy, comprising a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

The World Health Organization (WHO), the European Cancer Patient Coalition, and the National Cancer Institute are a few of the major primary and secondary sources referred to while preparing the report on the T cell therapy market.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医薬）の最新刊レポート

The Insight Partners社の製薬分野での最新刊レポート

本レポートと同じKEY WORD（car）の最新刊レポート

よくあるご質問

The Insight Partners社はどのような調査会社ですか?

The Insight Partnersはインドに本社を置く調査会社です。経験豊富な専門家チームを通じて、お客様に最適な調査と分析を提供することに専念しています。幅広い分野をカバーしていますがヘルスケ... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医薬）の最新刊レポート

The Insight Partners社の製薬分野での最新刊レポート

本レポートと同じKEY WORD（car）の最新刊レポート

よくあるご質問

The Insight Partners社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?